AzTrials
AzTrials

Parkinson DiseasePhase 2NCT05979415

Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

A Phase 2 study testing Apomorphine Cartridge in people with Parkinson Disease, run by Alexza Pharmaceuticals, Inc. at 13 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes. Read more about this study

Who is it for?
Ages 30 to 85 years
Conditions the study is for
Parkinson Disease
What is being tested?
Apomorphine Cartridge
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
8 participants
Where
13 sitesUnited States
Study dates
27 Sep 2023to 28 Feb 2024
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 1. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
  • 2. Willing and able to travel to the clinical research center and adhere to the overall study visit schedule, procedures, and other protocol requirements.
  • 3. Male or female between the ages of 30 and 85 (inclusive). 4. Body weight ≥ 50 kg. 5. Willing to abstain from alcohol for 6 hours prior to a study visit and minimize alcohol use throughout the study duration.
  • 6. Have a clinical diagnosis of PD; with fulfillment of Steps 1 and 2 of the UK Parkinson's Disease Brain Bank Criteria.
  • 7. Optimized and stabilized on oral dopaminergic therapy including levodopa at least 3 times daily and in combination with decarboxylase inhibitor at least 30 days prior to screening.
  • 8. Classified as Modified Hoehn \& Yahr stage II-IV in the ON state at Visit 1. 9. Have an MDS-UPDRS III score of at least 30 in the OFF state prior to the L-dopa challenge at Visit 2.
Show all 37Show fewer
  • 10. Experience self-described motor fluctuations (confirmed by the Motor Fluctuation Questionnaire at Screening) with recognizable OFF periods while on optimized oral l-dopa or dopamine agonist therapy.
  • 11. Experience at least 2 hours of OFF time per day and show responsiveness to levodopa (defined by a ≥ 30% reduction in MDS-UPDRS III score compared to pre-dose) at Visit 2.
  • 12. Female subjects, who are not pregnant or breastfeeding, and one of the following conditions applies: 13. Surgically sterile (including bilateral tubal ligation) for at least 3 months prior to screening.
  • Postmenopausal, defined as 1 of the following:
  • Last menstrual sequence greater than 12 months prior to screening
  • Last menstrual sequence greater than 6 months prior to screening and a serum follicle-stimulating hormone (FSH) concentration > 40 mIU/mL
  • Of childbearing potential (i.e., do not meet the criteria outlined above), patient must:
  • Have a negative urine pregnancy test at Screening and Day -1, as verified by the study doctor prior to starting study therapy.
  • Either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with, effective contraception without interruption with one of the following methods during the study participation up until 30 days after administration of study drug:
  • Oral contraceptive medications; Intra uterine devices; Hormonal implants; Injectable contraceptive medications; Double-barrier methods 14. Male subjects must practice true abstinence from heterosexual contact or, during sexual contact with a pregnant female or a female of childbearing potential, agree to use a condom or have had vasectomy with negative semen analysis and refrain from sperm donation during the duration of the study and up to 90 days after last dose of study drug.
  • Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
  • Willing and able to travel to the clinical research center and adhere to the overall study visit schedule, procedures, and other protocol requirements.
  • Male or female between the ages of 30 and 85 (inclusive).
  • Body weight ≥ 50 kg.
  • Willing to abstain from alcohol for 6 hours prior to a study visit and minimize alcohol use throughout the study duration.
  • Have a clinical diagnosis of PD; with fulfillment of Steps 1 and 2 of the UK Parkinson's Disease Brain Bank Criteria.
  • Optimized and stabilized on oral dopaminergic therapy including levodopa at least 3 times daily and in combination with decarboxylase inhibitor at least 30 days prior to screening.
  • Classified as Modified Hoehn \& Yahr stage II-IV in the ON state at Visit 1.
  • Have an MDS-UPDRS III score of at least 30 in the OFF state prior to the L-dopa challenge at Visit 2.
  • Experience self-described motor fluctuations (confirmed by the Motor Fluctuation Questionnaire at Screening) with recognizable OFF periods while on optimized oral l-dopa or dopamine agonist therapy.
  • Experience at least 2 hours of OFF time per day and show responsiveness to levodopa (defined by a ≥ 30% reduction in MDS-UPDRS III score compared to pre-dose) at Visit 2.
  • Female subjects, who are not pregnant or breastfeeding, and one of the following conditions applies:
  • Surgically sterile (including bilateral tubal ligation) for at least 3 months prior to screening.
  • Postmenopausal, defined as 1 of the following:
  • Last menstrual sequence greater than 12 months prior to screening
  • Last menstrual sequence greater than 6 months prior to screening and a serum follicle-stimulating hormone (FSH) concentration > 40 mIU/mL
  • Of childbearing potential (i.e., do not meet the criteria outlined above), patient must:
  • Have a negative urine pregnancy test at Screening and Day -1, as verified by the study doctor prior to starting study therapy.
  • Either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with, effective contraception without interruption with one of the following methods during the study participation up until 30 days after administration of study drug:
  • Oral contraceptive medications; Intra uterine devices; Hormonal implants; Injectable contraceptive medications; Double-barrier methods
  • Male subjects must practice true abstinence from heterosexual contact or, during sexual contact with a pregnant female or a female of childbearing potential, agree to use a condom or have had vasectomy with negative semen analysis and refrain from sperm donation during the duration of the study and up to 90 days after last dose of study drug.

Who cannot join

  • Subjects eligible for enrollment in the study must meet all of the following inclusion criteria and none of the exclusion criteria.
  • Previous significant complications from oral dopamine agonist therapy including hospitalization, hallucinations, or any other clinically relevant neuropsychiatric adverse event. Known intolerance to apomorphine.
  • Inhaled or sublingual apomorphine or inhaled l-dopa treatments during the trial.
  • Expected use of Apokyn or Kynmobi during the titration and treatment phase of the study.
  • Participation in earlier AZ-009 clinical trials.
  • Patients with suicidal behavior occurring within the past year or who pose a current suicide risk as determined by the PI or as confirmed at the first Screening Visit, the L-dopa challenge Visit (Visit -2) or Day 1 (Visit 3) by affirmative answer on items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS).
Show all 28Show fewer
  • Symptomatic clinically relevant and medically uncontrolled orthostatic hypotension or systolic blood pressure less than 100 mmHg at Screening or Baseline. Orthostatic hypotension is defined as a decrease in systolic blood pressure of 20 mm Hg > or a decrease in diastolic blood pressure > 10 mm Hg, or increase in heart rate > 20 BPM, when standing compared with blood pressure from the supine position.
  • Any clinically significant or unstable medical or psychiatric condition, as determined by the PI, based on a medical evaluation including history, physical examination, vital signs, electrocardiograms (ECGs), and laboratory tests assessed at the screening visit and prior to the first dose of study drug that could compromise the participant's safety or interfere with the completion of this protocol. A patient with a non-clinically significant abnormality or laboratory parameters outside the reference range may continue with the approval of the Investigator.
  • Subjects with a prolonged QT interval corrected for heart rate according to Fridericia's formula (QTcF) of >450 ms for male and >470 ms for female at screening or directly prior to first dosing, or a history of long QT syndrome. Also subjects with a PR interval > 220 msec or QRS duration > 120 msec at screening.
  • Currently taking, or may need treatment with, nitroglycerine
  • Any documented active or suspected or history of malignancy within 5 years prior to Visit 1, except appropriately treated basal cell carcinoma.
  • Active hallucinations or history of hallucinations in the past 3 months. Any significant medical condition, psychiatric illness, current major uncontrolled depression or bipolar disease, or history of depression that could, in the investigator's opinion, compromise the subject's safety or interfere with the completion of this protocol.
  • Dementia indicated by MMSE <24 at Screening.
  • History of clinically significant central nervous system (e.g., seizures), cardiac, pulmonary (e.g., asthma, COPD), metabolic, renal, hepatic, or gastrointestinal (GI) conditions including gastric bypass or other weight loss surgical procedure; or history of such conditions that, in the opinion of the investigator, may place the subject at an unacceptable risk as a participant in this trial, may interfere with the interpretation of safety and/or tolerability data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of the study drugs.
  • Screening FEV1 < 50% of predicted or FEV1/FVC ratio < 60% in the ON state at Visit 1.
  • Any condition including the presence of laboratory abnormalities, which according to the investigator places the subject at unacceptable risk if he/she were to participate in the study.
  • Aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), serum creatinine, or total bilirubin > 1.5 x upper limit of normal (ULN) at screening or prior to the first dose of study drug. An exception may be made for suspected Gilbert's syndrome. These laboratory tests may be repeated once, if they are abnormal on first screening, and if there is a medical reason to believe the results may be inaccurate. If the repeat test is within the reference range, the subject may be included only if the investigator considers that the previous finding will not compromise the subject's safety and will not interfere with the interpretation of safety data.
  • Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody at screening.
  • History of drug or alcohol abuse within 6 months of screening.
  • Positive drug screen at baseline. May not be exclusionary with a prescription.
  • History of any smoking/vaping (tobacco, cannabinoids) or any tobacco product use within 3 months prior to the study.
  • Participation in a clinical trial and receipt of an investigational medication or a new chemical entity within 30 days, 5 half-lives, if known, or twice the duration of the biological effect of any medication (whichever is longer) prior to the first dose of current study drug.
  • Use of medication that is inhibitor or inducer of CYP450-3A4/5 within 3 days of dosing.
  • Donation of blood, plasma or other blood products or blood collection in excess of 470 mL within 8 weeks prior to dosing.
  • Known sensitivity to any of the study drugs or components thereof, or a history of medication allergy or other allergy that, in the opinion of the investigator, contraindicates study participation.
  • Major surgery within 4 weeks of screening that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator.
  • Use of 5HT3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron during the trial.
  • Medications to treat gastroparesis (Antiemetics) or any dopamine antagonist.

Trial locations and contacts

13 sites in 1 country.

13 sites in 1 country

United States13 sites

  • Bradenton Research Center, Inc.

    Bradenton, Florida, 34205

  • CenExel iResearch Atlanta (Decatur)

    Decatur, Georgia, 30030

  • Cenexel Rocky Mountain Clinical Research

    Englewood, Colorado, 80113

  • Quest Research Institute

    Farmington Hills, Michigan, 48334

  • Holy Cross Health

    Fort Lauderdale, Florida, 33308

  • The Parkinson's and Movement Disorder Institute

    Fountain Valley, California, 92708

  • KCA Neurology, (Part of Ki Health Partners, LLC)

    Franklin, Tennessee, 37067

  • Lone Star Neurology, (Part of Ki Health Partners, LLC)

    Frisco, Texas, 75035

  • Visionary Investigators Network

    Miami, Florida, 33133

  • Parkinson's Disease Treatment Center of Southwest Florida

    Port Charlotte, Florida, 33980

  • Movement Disorders Center of Arizona

    Scottsdale, Arizona, 85258

  • Accellacare of Piedmont Healthcare

    Statesville, North Carolina, 28265

  • Tuscon Neuroscience Research (M3 Wake Research)

    Tucson, Arizona, 85710

Other trials in United States

About this study

Official title: A Randomized, Double-Blind, to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.

Read the detailed description

The purpose of this protocol is to establish the safety, tolerability, and efficacy of AZ-009 compared to placebo in patients with established PD experiencing daily OFF episodes.

Patients between the ages of 30 and 85 with a clinical diagnosis of established PD who experience motor fluctuation and have recognizable OFF periods are eligible for participation in this study. The patients will be classified as Modified Hoehn \& Yahr stage II-IV in the ON state and have clear, self-described daily motor fluctuations while on oral l-dopa or Carbidopa (with or without adjunctive PD therapy).

This study will be conducted in approximately 50 patients, with up to 8 Open-Label titration in-clinic visits with treatment at home between visits. This is followed by Double Blind which includes a 13 day treatment at home period, and an in-clinic visit and an End of Study/Early Termination visit for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.

Being tested
Apomorphine Cartridge
Keywords
OFF episode
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Apomorphine CartridgeDrug

    Also called placebo

    Staccato Cartridge

Study groups in NCT05979415
Study groupRoleWhat they receive
Staccato ApomorphineActive comparator1mg, 2mg, 3mg, 4mg
Receives: Drug: Apomorphine Cartridge
Staccato PlaceboPlacebo comparatorPlacebo
Receives: Drug: Apomorphine Cartridge

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. MDS-Unified Parkinson's Disease Rating Scale

    The MDS-UPDRS is a revision of the Unified Parkinson's Disease Rating Scale (UPDRS) and was developed to evaluate various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications.

    Measured: at 10, 20, 30 and 45 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Aug 2023
  2. Study start27 Sep 2023
  3. Primary completion28 Feb 2024
  4. Study completion28 Feb 2024

Why it stopped: Administrative decision

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05979415
Sponsor's protocol ID
AMDC 009-201
Status last verified
Mar 2024
First submitted
28 Jul 2023
Last updated
21 Oct 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Apomorphine Cartridge in people with Parkinson Disease, run by Alexza Pharmaceuticals, Inc. at 13 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 37 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 21 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 13 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: Administrative decision). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

MDS-Unified Parkinson's Disease Rating Scale (time frame: at 10, 20, 30 and 45 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05979415.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in